Abstract
The bioavailability after oral administration of (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro [4,5] decane-l-tartarate monohydrate (YM796), which is being developed as an antidementia drug, at a dose of 1 mg/kg was very low (3.4%) in rats, but considerably higher (16.1%) in dogs. The oral clearances (CLoral, Dose/AUCoral) in rats and dogs were, respectively, 300 and 18 times more than that already reported in humans. We have previously reported successful attempts to predict the in vivohepatic metabolic clearance of YM796 from in vitro data in humans. In our study, the in vitro metabolism of YM796 was determined using liver microsomes prepared from both rats and dogs and we also investigated if the species difference observedin vivo could be quantitatively reproduced in vitro. In rats, total metabolite formation could be described by single component kinetics with a Km of 13.4 μM and a Vmax of 520 nmol/min/g liver. However, in dogs, total metabolite formation could be described by three components, as also reported for humans. TheKm and Vmax values for the high-affinity, low-capacity component (Km1 and Vmax1) in dogs and humans were, respectively, 8.1 and 1.7 μM, and 10.9 and 1.2 nmol/min/g liver. The overall intrinsic metabolic clearances estimated from the in vitro studies (CLint,in vitro) for rats and dogs were 38.8 and 2.6 ml/min/g liver, respectively, being approximately 40 and 3 times more than that previously reported for humans (0.94 ml/min/g liver). The overall intrinsic hepatic clearances (CLint,in vivo) calculated from in vivo CLoral were 30.4, 3.4 and 0.73 ml/min/g liver for rats, dogs and humans, respectively, indicating that the in vivo hepatic clearance of YM796 can be predicted from in vitro metabolism data in each species. Thus, the pronounced species difference in the metabolic clearance observedin vivo can be quantitatively predicted from in vitro metabolic data using liver microsomes, and was predominantly due to the large difference in the Vmaxvalues.
Footnotes
-
Send reprint requests to: Dr.Yuichi Sugiyama, Faculty of Pharmaceutical Sciences, The University of Tokyo, 7–3-1, Hongo, Bunkyo-ku, Tokyo 113, Japan.
- Abbreviations:
- AUCoral
- area under the plasma concentration-time curve after oral administration
- CLh
- hepatic clearance
- CLint,all
- overall intrinsic metabolic clearance (intrinsic hepatic clearance)
- CLint,in vitro
- overall intrinsic metabolic clearance estimated from the in vitro study
- CLint,in vivo
- overall intrinsic hepatic clearance calculated based on the in vivopharmacokinetic information
- CLns
- intrinsic metabolic clearance for the nonsaturable component
- CLoral
- oral clearance (= Dose/AUCoral)
- CLr
- renal clearance
- CLtot
- total body clearance
- CYP
- cytochrome P-450
- DN
- dispersion number
- Fa
- the fraction absorbed from the intestinal tract
- Fh
- hepatic availability
- fb
- unbound fraction in blood
- fp
- unbound fraction in plasma
- GC
- gas chromatography
- Km,i
- Michaelis-Menten constant for the i-th component of the metabolic reaction
- MS
- microsomal
- MS-MS
- tandem mass spectrometry
- Qh
- hepatic blood flow rate
- RB
- blood-to-plasma concentration ratio
- TLC
- thin-layer chromatography
- Vmax,i
- maximum metabolic rate for the i-th component of the metabolic reaction
- Received January 29, 1997.
- Accepted July 8, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|